Cargando…
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519142/ https://www.ncbi.nlm.nih.gov/pubmed/36187874 http://dx.doi.org/10.1097/HS9.0000000000000781 |
| _version_ | 1784799329761886208 |
|---|---|
| author | Winkelmann, Michael Rejeski, Kai Blumenberg, Viktoria Bücklein, Veit L. Ruzicka, Michael Unterrainer, Marcus Schmidt, Christian Dekorsy, Franziska J. Bartenstein, Peter Ricke, Jens von Bergwelt-Baildon, Michael Subklewe, Marion Kunz, Wolfgang G. |
| author_facet | Winkelmann, Michael Rejeski, Kai Blumenberg, Viktoria Bücklein, Veit L. Ruzicka, Michael Unterrainer, Marcus Schmidt, Christian Dekorsy, Franziska J. Bartenstein, Peter Ricke, Jens von Bergwelt-Baildon, Michael Subklewe, Marion Kunz, Wolfgang G. |
| author_sort | Winkelmann, Michael |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9519142 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95191422022-09-30 Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival Winkelmann, Michael Rejeski, Kai Blumenberg, Viktoria Bücklein, Veit L. Ruzicka, Michael Unterrainer, Marcus Schmidt, Christian Dekorsy, Franziska J. Bartenstein, Peter Ricke, Jens von Bergwelt-Baildon, Michael Subklewe, Marion Kunz, Wolfgang G. Hemasphere Letter Lippincott Williams & Wilkins 2022-09-27 /pmc/articles/PMC9519142/ /pubmed/36187874 http://dx.doi.org/10.1097/HS9.0000000000000781 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Letter Winkelmann, Michael Rejeski, Kai Blumenberg, Viktoria Bücklein, Veit L. Ruzicka, Michael Unterrainer, Marcus Schmidt, Christian Dekorsy, Franziska J. Bartenstein, Peter Ricke, Jens von Bergwelt-Baildon, Michael Subklewe, Marion Kunz, Wolfgang G. Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival |
| title | Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival |
| title_full | Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival |
| title_fullStr | Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival |
| title_full_unstemmed | Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival |
| title_short | Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival |
| title_sort | chimeric antigen receptor t-cell therapy: imaging response criteria and relation to progression-free and overall survival |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519142/ https://www.ncbi.nlm.nih.gov/pubmed/36187874 http://dx.doi.org/10.1097/HS9.0000000000000781 |
| work_keys_str_mv | AT winkelmannmichael chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT rejeskikai chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT blumenbergviktoria chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT buckleinveitl chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT ruzickamichael chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT unterrainermarcus chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT schmidtchristian chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT dekorsyfranziskaj chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT bartensteinpeter chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT rickejens chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT vonbergweltbaildonmichael chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT subklewemarion chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival AT kunzwolfgangg chimericantigenreceptortcelltherapyimagingresponsecriteriaandrelationtoprogressionfreeandoverallsurvival |